MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Author MStranslate

MStranslate

Facebook Live

Facebook Live: Funding Multiple Sclerosis Research

MStranslate
December 18, 2018
Community, Research
On December 12, 2018, Brett Drummond (our Co-Founder and Chief Science Communicator) held a Facebook Live event to explore the issue of how multiple sclerosis research is...
smell

The Nose Knows: Can Smell Be A Marker Of MS Progression?

MStranslate
December 6, 2018
Research
Research Summary: Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration WHAT? A research study investigating whether specific...
treatment decision

What influences the choice of treatment in MS?

MStranslate
November 28, 2018
Research, Treatments, Uncategorized
Research Summary: Understanding treatment decisions from the perspective of people with relapsing remitting multiple sclerosis: A critical interpretive synthesis The past decade has seen a number of new...
T Cell Therapy

EBV-Specific T Cell Therapy for Progressive MS

MStranslate
November 20, 2018
Epstein-Barr virus, Infection, Progressive MS, Research, Treatments
Research Summary: Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis Last week, during our Facebook Live Q&A, we discussed the potential role of Epstein-Barr Virus or EBV in...
Gut Microbiome

ECTRIMS 2018: The Gut Microbiome in MS

MStranslate
November 19, 2018
Conferences, ECTRIMS, Research
1 Comment
"It is intriguing...can you modulate the gut microbiome to improve outcomes in MS, such as reducing relapse rates? That would be a fabulous end goal!" - Prof Helen Tremlett. The potential role of the gut...
ECTRIMS Congress 2018

ECTRIMS Congress 2018 Coverage – Day 3

MStranslate
October 18, 2018
Conferences, ECTRIMS, Research
1 Comment
This year, MStranslate invested in travelling to the ECTRIMS Congress 2018, recognising it’s the easiest and most efficient way to inform our online communities of the important insights and outcomes being...
ECTRIMS Congress 2018

ECTRIMS Congress 2018 Coverage – Day 2

MStranslate
October 15, 2018
Conferences, ECTRIMS, Research
2 Comments
This year, MStranslate invested in travelling to the ECTRIMS Congress 2018, recognising it’s the easiest and most efficient way to inform our online communities of the important insights and outcomes being...
ECTRIMS Congress 2018

ECTRIMS Congress 2018 Coverage – Day 1

MStranslate
October 11, 2018
Conferences, ECTRIMS, Research
2 Comments
This year, MStranslate has invested in travelling to the ECTRIMS Congress 2018, recognising it's the easiest and most efficient way to inform our online communities of the important insights and outcomes being...
Ocrevus

Ocrevus and PPMS: Where to from here?

MStranslate
September 10, 2018
Ocrelizumab, Opinion, Treatments
The following is an opinion piece written by MStranslate co-founder, Brett Drummond. Let’s rewind to last March last year…there is worldwide excitement as ocrelizumab (Ocrevus) becomes the first treatment...
ibudilast

Ibudilast Phase 2 Trial Results for Progressive MS

MStranslate
August 30, 2018
Progressive MS, Research, Treatments
Research Summary: Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis What is it? Ibudilast is an anti-inflammatory treatment, which also has effects that protect nerves.  It is thought to offer...
  1. 9
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.